We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

133 hedge funds and large institutions have $1.3B invested in Intra-Cellular Therapies Inc. in 2019 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 47 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

337% more capital invested

Capital invested by funds: $298M → $1.3B (+$1B)

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

6% more funds holding

Funds holding: 126 → 133 (+7)

23% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 47

53% less call options, than puts

Call options by funds: $260M | Put options by funds: $549M

Holders
133
Holders Change
+7
Holders Change %
+5.56%
% of All Funds
2.62%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.08%
New
31
Increased
36
Reduced
47
Closed
24
Calls
$260M
Puts
$549M
Net Calls
-$289M
Net Calls Change
-$278M

Top Buyers

1
CCM
Consonance Capital Management
New York
+$23.5M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$14.6M
3
ACP
Acuta Capital Partners
California
+$7.05M
4
VMI
VHCP Management III
New York
+$6.9M
5
OM
Opaleye Management
Massachusetts
+$2.84M

Top Sellers

1
WA
Wasatch Advisors
Utah
-$26.8M
2
Millennium Management
Millennium Management
New York
-$11.7M
3
SC
Samlyn Capital
New York
-$11M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$8.11M
5
ClearBridge Investments
ClearBridge Investments
New York
-$5.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
101
Creative Planning
Kansas
$319K +$112K +9,300 New
Arrowstreet Capital
102
Arrowstreet Capital
Massachusetts
$298K +$104K +8,700 New
Ameriprise
103
Ameriprise
Minnesota
$288K +$101K +8,386 New
Principal Financial Group
104
Principal Financial Group
Iowa
$276K +$96.7K +8,054 New
Royal Bank of Canada
105
Royal Bank of Canada
Ontario, Canada
$275K -$140K -11,644 -59%
AB
106
Amalgamated Bank
New York
$275K +$96.1K +8,009 New
Susquehanna International Group
107
Susquehanna International Group
Pennsylvania
$239K -$403K -33,571 -83%
Janney Montgomery Scott
108
Janney Montgomery Scott
Pennsylvania
$233K +$81.5K +6,787 New
JSMC
109
Jess S. Morgan & Co
California
$223K +$78K +6,500 New
Rafferty Asset Management
110
Rafferty Asset Management
New York
$222K -$73.2K -6,096 -48%
PP
111
PDT Partners
New York
$214K -$1.48M -123,512 -95%
BNP Paribas Financial Markets
112
BNP Paribas Financial Markets
France
$214K -$22.6K -1,887 -23%
Public Employees Retirement Association of Colorado
113
Public Employees Retirement Association of Colorado
Colorado
$195K – – –
FANJ
114
Financial Architects (New Jersey)
New Jersey
$172K +$60K +5,000 New
Canada Life
115
Canada Life
Manitoba, Canada
$143K +$50.5K +4,208 New
AIP
116
Ameritas Investment Partners
Nebraska
$128K – – –
VCP
117
Verus Capital Partners
Arizona
$103K +$36K +3,000 New
Zurich Cantonal Bank
118
Zurich Cantonal Bank
Switzerland
$92K – – –
PNC Financial Services Group
119
PNC Financial Services Group
Pennsylvania
$77K +$1.9K +158 +8%
AIM
120
Aigen Investment Management
New York
$41K +$14.4K +1,199 New
BWP
121
Baldwin Wealth Partners
Massachusetts
$34K – – –
BCM
122
Blume Capital Management
California
$34K – – –
KTC
123
Kistler-Tiffany Companies
Pennsylvania
$34K +$12K +1,000 New
MAM
124
Meeder Asset Management
Ohio
$26K -$4.91K -409 -36%
US Bancorp
125
US Bancorp
Minnesota
$18K +$4.56K +380 +257%
3 4
5
6 7

ITCI Hedge Fund Activity: Q4 2019 in Review

133 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2019, worth a combined $1.3B — up 337% from $298M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ITCI positions and 24 closed out — a net gain of 7 holders — while 36 added to existing stakes and 47 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $23.5M. The largest seller was Wasatch Advisors, cutting an estimated $26.8M.

  • 133 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2019, up from 126 in Q3 2019.
  • Funds reported $1.3B of Intra-Cellular Therapies Inc. stock for Q4 2019, up 337% quarter-over-quarter.
  • 31 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2019 and 24 closed out, a net change of +7 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2019 was Consonance Capital Management, an estimated $23.5M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2019 was Wasatch Advisors, an estimated $26.8M sold.

Based on aggregated 13F filings for Q4 2019.